HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 475 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells June 14, 2019 EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib July 29, 2021 Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 9, 2020 GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... February 2, 2021 Load more HOT NEWS Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar... Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal... Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis
